MAP2K7 and exstrophy-epispadias complex: While our study is the first to investigate the preclinical activity of the novel RAF/MEK clamp avutometinib, the focal adhesion kinase inhibitor defactinib or their combination against primary EEC cell lines and xenografts it has limitations.